OTCMKTS:ENDV Endonovo Therapeutics (ENDV) Stock Price, News & Analysis $0.0003 +0.00 (+50.00%) As of 03/24/2025 03:54 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartFinancialsSEC FilingsShort InterestBuy This Stock About Endonovo Therapeutics Stock (OTCMKTS:ENDV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Endonovo Therapeutics alerts:Sign Up Key Stats Today's Range$0.0002▼$0.000350-Day Range N/A52-Week Range$0.0001▼$0.0058Volume347.58 million shsAverage Volume31.36 million shsMarket Capitalization$329,376.30P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEndonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.Read More… Remove Ads Receive ENDV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Endonovo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ENDV Stock News HeadlinesEndonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, IncMarch 28, 2024 | globenewswire.comEndonovo’s SofPulse® to Be Featured at Innovative Pain Management SolutionsMarch 4, 2024 | finance.yahoo.com“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... But today, Chris is now making the biggest crypto call of his ENTIRE career…March 25, 2025 | True Market Insiders (Ad)Endonovo's SofPulse® to Be Featured at Innovative Pain Management SolutionsMarch 4, 2024 | globenewswire.comEndonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 MillionDecember 4, 2023 | finance.yahoo.comEndonovo Therapeutics, Inc. (ENDV)November 21, 2023 | finance.yahoo.comLexeo Therapeutics Inc (LXEO)November 15, 2023 | investing.comEndonovo receives Taiwanese approval for SofPulse technologyOctober 13, 2023 | msn.comSee More Headlines ENDV Stock Analysis - Frequently Asked Questions How have ENDV shares performed this year? Endonovo Therapeutics' stock was trading at $0.0004 at the start of the year. Since then, ENDV stock has decreased by 25.0% and is now trading at $0.0003. View the best growth stocks for 2025 here. How do I buy shares of Endonovo Therapeutics? Shares of ENDV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Endonovo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Endonovo Therapeutics investors own include Chesapeake Energy (CHKAQ), Novavax (NVAX), Energous (WATT), Advanced Micro Devices (AMD), BioLineRx (BLRX), Citigroup (C) and Ekso Bionics (EKSO). Company Calendar Today3/25/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Electromedical equipment Sub-IndustryMedical Equipment Current SymbolOTCMKTS:ENDV CIK1528172 Webwww.endonovo.com Phone(800) 489-4774Fax818-230-9899Employees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$140,000.00 Price / Sales2.35 Cash Flow$0.03 per share Price / Cash Flow0.01 Book Value($0.08) per share Price / Book0.00Miscellaneous Outstanding Shares1,097,921,000Free Float885,602,000Market Cap$329,376.30 OptionableNot Optionable Beta-1.66 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (OTCMKTS:ENDV) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Endonovo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Endonovo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.